Roche Finally Ready To Make Its Mark In PD-1/L1 Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing for PD-L1 inhibitor atezolizumab (MPDL3280A) in bladder cancer expected after positive top-line Phase II release; full data could come at European Society for Medical Oncology meeting this fall.